The Latest Breaking News from AMGN

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

Amgen has outperformed the S&P 500, and analysts remain optimistic about the stock’s prospects because of the positive Phase 2 clinical trial data of its obesity drug MariTide.

Drug manufacturer Amgen Inc. (AMGN) is actively pursuing strategic collaborations and making noteworthy strides in the realm of obesity treatments. With the company all set to lift the curtains on its fiscal fourth-quarter earnings tomorrow, would it be prudent to take a bullish stance on the stock now? Keep reading…

With technology revolutionizing drug discovery, the biotech sector thrives on innovation and breakthrough therapies. Hence, let's delve into and analyze the gain potential of fundamentally strong biotech stocks Amgen (AMGN), Alkermes (ALKS), and Vertex Pharmaceuticals (VRTX). Read more….

The biotech industry is well-positioned to generate returns amid breakthrough developments and the growing prevalence of chronic diseases. Given the solid long-term prospects of the industry, fundamentally sound biotech stocks Entrada Therapeutics (TRDA), Alkermes (ALKS) and Amgen (AMGN) could be ideal buys for steady gains. Read on.

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

Given the breakthrough developments, government support, and rising need to treat chronic diseases, the biotech industry is well-positioned to grow steadily. So, it could be wise to invest in quality biotech stocks Alkermes (ALKS), Amgen (AMGN) and Incyte (INCY). Read on….